BO

BOLAK CO.,LTD

Manufacturer of specialty ingredients for the food, pharmaceutical, and cosmetic industries.

002760 | KO

Overview

Corporate Details

ISIN(s):
KR7002760007
LEI:
Country:
South Korea
Address:
경기도 화성시 양감면 초록로 720-37, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1959, Bolak Co., Ltd. is a manufacturer of specialty ingredients and raw materials. The company serves the food, pharmaceutical, and cosmetic industries with a diverse product portfolio. Key offerings include food additives such as flavors, coloring agents, and gum base, for which it was a domestic pioneer. The company also develops and produces active pharmaceutical ingredients (APIs), with specialized capabilities for high-potency compounds, as well as functional food materials and cosmetic and botanical extracts for a global and domestic customer base.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 83.3 KB
2025-08-13 00:00
Interim / Quarterly Report
반기보고서 (2025.06)
Korean 749.3 KB
2025-08-07 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.6 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 757.2 KB
2025-04-28 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 13.6 KB
2025-03-31 00:00
AGM Information
정기주주총회결과
Korean 19.2 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 11.5 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 949.2 KB
2025-03-18 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 20.6 KB
2025-03-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 213.3 KB
2025-03-14 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.3 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 128.2 KB
2025-03-14 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 12.4 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 9.1 KB
2024-12-09 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB

Automate Your Workflow. Get a real-time feed of all BOLAK CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BOLAK CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BOLAK CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA

Talk to a Data Expert

Have a question? We'll get back to you promptly.